Avalyn Pharma Inc.
AVLNNasdaq
$28.30
↑ +10.2%Jul 17 close · end-of-day
Price
1Y↓ -4.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our principal executive offices are located in Boston, Massachusetts.
- CEO
- Lyn Baranowski
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 51
- Headquarters
- Massachusetts
- Website
- www.avalynpharma.com
Earnings
AVLN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$21.83↓ -65.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
No annual data.
| Line item | Q1 '25 | Q1 '26 |
|---|---|---|
| Revenue | — | — |
| Gross profit | — | — |
| Operating income | -$18.7M | -$27.9M |
| Net income | -$17.5M | -$26.9M |
| Diluted EPS | -$63.24 | -$21.83 |
| Operating cash flow | -$19.3M | -$29.9M |
| Free cash flow | -$19.3M | -$30.2M |
| Gross margin | — | — |
| Operating margin | — | — |
| Net margin | — | — |
Company news
Jun 6, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-01 | Novo A/S | Buy | 555,555 | $18.00 | $10.0M | filing |
| 2026-05-01 | Carroll Jill | Buy | 277,778 | $18.00 | $5.0M | filing |
| 2026-05-01 | SR ONE CAPITAL MANAGEMENT, LLC | Buy | 277,778 | $18.00 | $5.0M | filing |
| 2026-05-01 | SR ONE CAPITAL MANAGEMENT, LLC | Buy | 277,777 | $18.00 | $5.0M | filing |
| 2026-05-01 | FMR LLC | C | 225,843 | — | — | filing |
| 2026-05-01 | FMR LLC | C | 377,948 | — | — | filing |
| 2026-05-01 | Carroll Jill | C | 1,419,298 | — | — | filing |
| 2026-05-01 | Carroll Jill | C | 489,486 | — | — | filing |
| 2026-05-01 | SR ONE CAPITAL MANAGEMENT, LLC | C | 1,419,298 | — | — | filing |
| 2026-05-01 | SR ONE CAPITAL MANAGEMENT, LLC | C | 489,486 | — | — | filing |
| 2026-05-01 | SR ONE CAPITAL MANAGEMENT, LLC | C | 354,824 | — | — | filing |
| 2026-05-01 | SR ONE CAPITAL MANAGEMENT, LLC | C | 489,486 | — | — | filing |
| 2026-05-01 | Novo A/S | C | 3,327,734 | — | — | filing |
| 2026-05-01 | Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | C | 1,275,486 | — | — | filing |
| 2026-05-01 | FMR LLC | C | 727,585 | — | — | filing |
| 2026-05-01 | FMR LLC | C | 80,291 | — | — | filing |
| 2026-05-01 | FMR LLC | C | 872,868 | — | — | filing |
Latest 17 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.